"instanceType","label","name","uuid:ID","description","id","rationale"
"StudyDesign","","Study Design 1","09aecb4f-ae1d-4d9f-b877-32b9bf8f26b5","The main design for the study","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
